4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is a Healthcare company (Biotechnology) with a market capitalization of $596M. The Maz Rating grades it against the other companies in its sector.
4D Molecular Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $10.79, 4D Molecular Therapeutics, Inc. trades at 6.2x sales and 2.3x book value. Over the last twelve months it generated about $96M of revenue and a net loss of $154M. It runs a gross margin of 91.5%, an operating margin of -226.0% and a net margin of -208.6%. It shows return on equity of -47.1%, return on invested capital of -56.9% and a free cash flow yield of -28.1%. On the balance sheet: a debt-to-equity ratio of 0.11 and a current ratio of 6.15. Over the past 52 weeks the share price ranged from $6.96 to $16.93, with a beta of 2.91.
4D Molecular Therapeutics, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 11 Buy, 2 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, 4D Molecular Therapeutics, Inc. (FDMT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.07% / 30% · (Cash+Inv) / Mkt Cap (36m) 39.4% / 30% · Interest income / Revenue 95.1% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 2.07% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 32.3% / 33% · Receivables / Mkt Cap (36m) 0.42% / 49% · Interest income / Revenue 95.1% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 2.07% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 32.3% / 33.33% · Receivables / Mkt Cap (24m) 0.42% / 33.33% · Interest income / Revenue 95.1% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 1.96% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 73.1% / 33.33% · Receivables / Avg Assets (4Q) 0.43% / 33.33% · Interest income / Revenue 95.1% / 5% | Fail |
| FTSE | Debt / Total Assets 4.59% / 33.33% · (Cash+ST Inv) / Total Assets 71.6% / 33.33% · (Cash+Recv) / Total Assets 72.5% / 33.33% · Interest income / Revenue 95.1% / 5% | Fail |
No. As of September 2026, 4D Molecular Therapeutics, Inc. (FDMT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. 4D Molecular Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 95.1% of each dividend: 4D Molecular Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.